Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis
Harrer DC, Jakob M, Vogelhuber M, Lueke F, Utpatel K, Corbacioglu S, Herr W, Reichle A, Heudobler D (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 63
Pages Range: 2858-2868
Journal Issue: 12
DOI: 10.1080/10428194.2022.2095627
Abstract
Langerhans cell histiocytosis (LCH) is rare hematological neoplasia originating from the aberrant proliferation of CD207-positive dendritic cells. Refractory multi-system LCH is difficult to treat necessitating the continuous development of different salvage therapies. At our medical center, eleven patients (age 11 months to 77 years) with multi-system LCH were treated on a compassionate use basis with metronomic biomodulation therapy (MBT) involving the daily oral application of low-dose trofosfamide, etoricoxib, pioglitazone and low-dose dexamethasone. Overall, four patients including two heavily pretreated pediatric patients achieved ongoing complete remission. Moreover, partial disease remission was observed in three patients, and four patients attained stable disease. MBT demonstrated high activity against multi-system LCH even in patients, refractory to multiple systemic chemotherapies. Further confirmation of efficacy should be systematically evaluated in prospective trials.
Involved external institutions
Germany (DE)How to cite
APA:
Harrer, D.C., Jakob, M., Vogelhuber, M., Lueke, F., Utpatel, K., Corbacioglu, S.,... Heudobler, D. (2022). Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis. Leukemia & Lymphoma, 63(12), 2858-2868. https://doi.org/10.1080/10428194.2022.2095627
MLA:
Harrer, Dennis C., et al. "Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis." Leukemia & Lymphoma 63.12 (2022): 2858-2868.
BibTeX: Download